Rankings
▼
Calendar
AMRX Q2 2023 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
Q2 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$599M
+7.1% YoY
Gross Profit
$220M
36.7% margin
Operating Income
$80M
13.4% margin
Net Income
$12M
2.0% margin
EPS (Diluted)
$0.08
QoQ Revenue Growth
+7.4%
Cash Flow
Operating Cash Flow
-$11M
Free Cash Flow
-$24M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$3.7B
Total Liabilities
$3.5B
Stockholders' Equity
$318M
Cash & Equivalents
$109M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$599M
$559M
+7.1%
Gross Profit
$220M
$201M
+9.7%
Operating Income
$80M
-$199M
+140.3%
Net Income
$12M
-$121M
+109.9%
Revenue Segments
Generics Segment
$374M
62%
Av K A R E Segment
$128M
21%
Amneal Specialty Pharma Segment
$97M
16%
← FY 2023
All Quarters
Q3 2023 →